The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Adagio Therapeutics | Common Stock | 00534A102 | 26,732 | 632,855 | SH | SOLE | 632,855 | 0 | 0 | ||
Alpine Immune Sciences | Common Stock | 02083G100 | 21,656 | 2,029,580 | SH | SOLE | 2,029,580 | 0 | 0 | ||
Arcutis Biothereapeutics | Common Stock | 03969K108 | 14,903 | 623,836 | SH | SOLE | 623,836 | 0 | 0 | ||
Atea Pharmaceuticals | Common Stock | 04683R106 | 5,770 | 164,577 | SH | SOLE | 164,577 | 0 | 0 | ||
Checkmate Pharmaceuticals | Common Stock | 162818108 | 5,300 | 1,335,050 | SH | SOLE | 1,335,050 | 0 | 0 | ||
Cidara Therapeutics | Common Stock | 171757107 | 4,492 | 2,005,249 | SH | SOLE | 2,005,249 | 0 | 0 | ||
ESSA Pharma | Common Stock | 29668H708 | 2,626 | 328,196 | SH | SOLE | 328,196 | 0 | 0 | ||
FibroGen Inc | Common Stock | 31572Q808 | 1,150 | 130,646 | SH | SOLE | 130,646 | 0 | 0 | ||
Gossamer Bio | Common Stock | 38341P102 | 41,740 | 3,320,608 | SH | SOLE | 3,320,608 | 0 | 0 | ||
Icosavax | Common Stock | 45114M109 | 12,617 | 426,395 | SH | SOLE | 426,395 | 0 | 0 | ||
Ikena Oncology | Common Stock | 45175G108 | 28,384 | 2,249,123 | SH | SOLE | 2,249,123 | 0 | 0 | ||
Imago Biosciences | Common Stock | 45250K107 | 60,465 | 3,018,737 | SH | SOLE | 3,018,737 | 0 | 0 | ||
Immunic Inc | Common Stock | 4525EP101 | 15,825 | 1,788,160 | SH | SOLE | 1,788,160 | 0 | 0 | ||
Immunocore Holdings | Common Stock | 45258D105 | 1,910 | 51,535 | SH | SOLE | 51,535 | 0 | 0 | ||
Jounce Therapeutics | Common Stock | 481116101 | 2,047 | 275,513 | SH | SOLE | 275,513 | 0 | 0 | ||
Kronos Bio | Common Stock | 50107A104 | 80,031 | 3,818,283 | SH | SOLE | 3,818,283 | 0 | 0 | ||
Morphic Holding | Common Stock | 61775R105 | 74,536 | 1,315,952 | SH | SOLE | 1,315,952 | 0 | 0 | ||
Nuvation Bio | Common Stock | 67080N101 | 280,431 | 28,212,376 | SH | SOLE | 28,212,376 | 0 | 0 | ||
ObsEva SA | Common Stock | H5861P103 | 3,108 | 999,364 | SH | SOLE | 999,364 | 0 | 0 | ||
Omega Alpha SPAC | Common Stock | G6749V107 | 4,877 | 501,000 | SH | SOLE | 501,000 | 0 | 0 | ||
Paratek Pharmaceuticals | Common Stock | 699374302 | 12,669 | 2,606,809 | SH | SOLE | 2,606,809 | 0 | 0 | ||
Replimune Group | Common Stock | 76029N106 | 145,120 | 4,896,074 | SH | SOLE | 4,896,074 | 0 | 0 | ||
Sana Biotechnology, Inc. | Common Stock | 799566104 | 19,001 | 843,750 | SH | SOLE | 843,750 | 0 | 0 | ||
Spruce Biosciences | Common Stock | 85209E109 | 12,988 | 2,161,022 | SH | SOLE | 2,161,022 | 0 | 0 | ||
Syros Pharmaceuticals | Common Stock | 87184Q107 | 11,232 | 2,512,705 | SH | SOLE | 2,512,705 | 0 | 0 | ||
Trevi Therapeutics | Common Stock | 89532M101 | 1,769 | 1,263,408 | SH | SOLE | 1,263,408 | 0 | 0 |